Latuda is a medicine that is used to treat patients from 13 years of age with schizophrenia, a mental illness with symptoms that include disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Latuda contains the active substance lurasidone.
Latuda : EPAR - Medicine overview (PDF/128.82 KB)
First published: 08/04/2014
Last updated: 14/09/2020
Latuda : EPAR - Risk-management-plan summary (PDF/141.85 KB)
First published: 13/05/2014
Last updated: 17/03/2022
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Aziende Chimiche Riunite Angelini Francesco S.p.A.
|Date of issue of marketing authorisation valid throughout the European Union||
Viale Amelia 70
10/03/2022 Latuda - EMEA/H/C/002713 - II/0037
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment of schizophrenia in adults aged 18 years and over.